NCT06640049View on ClinicalTrials.gov

A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

October 24, 2027

Study Completion Date

April 15, 2031

Conditions
Neoplasms, Rectal
Interventions
BIOLOGICAL

Dostarlimab

Dostarlimab will be administered.

Trial Locations (8)

200032

RECRUITING

GSK Investigational Site, Shanghai

250117

RECRUITING

GSK Investigational Site, Jinan

400010

RECRUITING

GSK Investigational Site, Chongqing

510060

RECRUITING

GSK Investigational Site, Guangzhou

510655

RECRUITING

GSK Investigational Site, Guangzhou

610041

RECRUITING

GSK Investigational Site, Chengdu

Unknown

RECRUITING

GSK Investigational Site, Hangzhou

030013

RECRUITING

GSK Investigational Site, Taiyuan

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06640049 - A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China | Biotech Hunter | Biotech Hunter